Is CombiPatch or Climara Pro Safe While Trying to Conceive?

The short answer: no, neither patch is safe while trying to conceive

CombiPatch and Climara Pro are not fertility medications. They were designed for a specific population: postmenopausal or perimenopausal women with an intact uterus who need symptom relief and endometrial protection. The FDA-approved labeling for CombiPatch explicitly lists pregnancy as a contraindication, and the same applies to Climara Pro.

If you are trying to conceive, using either patch could expose a developing embryo or fetus to synthetic progestins at doses and receptor profiles that are not studied for this purpose. The risk is not theoretical. Stop now, and speak with your OB-GYN or reproductive endocrinologist before your next cycle.

Why these patches exist in the first place

Both patches were built to solve the "unopposed estrogen" problem in menopause. Estrogen alone thickens the uterine lining and raises endometrial cancer risk. Adding a progestin counteracts that effect. CombiPatch pairs estradiol 0.05 mg/day with norethindrone acetate 0.14 mg/day or 0.25 mg/day in a continuous-combined transdermal system. Climara Pro delivers estradiol 0.045 mg/day with levonorgestrel 0.015 mg/day.

Neither dose, neither progestin, and neither delivery route was studied in women of reproductive age trying to get pregnant.

What "contraindicated in pregnancy" actually means

A contraindication is not a soft advisory. It means the risks to the fetus, the pregnant woman, or both outweigh any conceivable benefit for that indication. ACOG guidance on hormone therapy in perimenopausal women notes that hormone therapy is intended for symptomatic management, not for women in the reproductive window who could become pregnant.

The FDA drug labeling for both CombiPatch and Climara Pro states directly that these products should be discontinued if pregnancy is confirmed. The implication for TTC is clear: you should not start these patches if pregnancy is possible, and you should stop before attempting conception.

Understanding the progestins: norethindrone and levonorgestrel

Not all progestins behave the same way in a pregnant body, and this distinction matters enormously when you are trying to conceive or are newly pregnant.

Norethindrone acetate (CombiPatch)

Norethindrone acetate is a 19-nortestosterone-derived synthetic progestin with moderate androgenic activity. In animal reproductive studies, norethindrone has produced virilization of female fetuses at doses relevant to systemic exposure. While large-scale human epidemiological studies have not confirmed a clear teratogenic signal at typical contraceptive doses, the mechanism for fetal androgen exposure is biologically plausible, and no safety data exist for the transdermal menopausal dose specifically in pregnant women.

Norethindrone is a known pregnancy Category X compound in older FDA classifications. The current labeling system dropped letter categories in 2015, replacing them with narrative risk summaries, but the underlying human and animal data remain the same. The FDA prescribing information for norethindrone-containing products states that the drug should not be used during pregnancy.

Levonorgestrel (Climara Pro)

Levonorgestrel is also a 19-nortestosterone derivative and carries higher androgenic potency than norethindrone on a per-milligram basis. Animal reproductive toxicity studies with levonorgestrel have shown fetal harm at doses producing plasma concentrations similar to human therapeutic levels. In humans, levonorgestrel is best known as an emergency contraceptive and long-acting IUD hormone, not a pregnancy-support progestin.

There are no randomized trials, cohort studies, or case series examining Climara Pro use specifically in women who are trying to conceive or who conceived while using the patch.

The progestin that does have TTC and early-pregnancy data

Micronized progesterone (bioidentical, oral or vaginal) is structurally identical to the progesterone your ovaries produce. It has a completely different receptor and metabolic profile from norethindrone or levonorgestrel. ASRM guidelines support vaginal micronized progesterone for luteal-phase support in assisted reproductive technology cycles, and it is widely used in early pregnancy for women at risk of miscarriage. If you need progesterone support while trying to conceive, this is the conversation to have with your reproductive endocrinologist, not one involving a menopausal patch.

Estradiol in the context of trying to conceive

The estradiol component of both patches is the same molecule your ovaries produce, but context and dose matter.

Natural estradiol vs. Patch-delivered estradiol

Your body regulates estradiol tightly across the menstrual cycle, rising from roughly 20-150 pg/mL in the follicular phase to a peak of 150-750 pg/mL at ovulation, then declining through the luteal phase. Transdermal estradiol from menopausal patches delivers a flat, continuous serum estradiol level typically in the 40-100 pg/mL range, bypassing first-pass hepatic metabolism. That continuous flatline does not mimic the natural cycle surge-and-drop pattern that coordinates ovulation, implantation, and early placentation.

There is no evidence that the estradiol component of CombiPatch or Climara Pro is harmful in isolation, but it cannot be separated from the synthetic progestin delivered simultaneously.

Estradiol in monitored fertility protocols

In IVF and frozen embryo transfer protocols, clinicians do use exogenous estradiol to prepare the uterine lining, but in carefully titrated doses, with cycle monitoring, and without the synthetic progestins found in these patches. That is a fundamentally different clinical scenario from using a menopausal combination patch while trying to conceive naturally or through IUI.

Pregnancy and lactation: what the data actually say

This section is required reading if you are pregnant, recently pregnant, or postpartum and were using either patch.

If you became pregnant while using CombiPatch or Climara Pro

Stop the patch immediately. Contact your OB-GYN or maternal-fetal medicine specialist the same day. Fetal exposure in the first trimester is the highest-concern window because organogenesis, including reproductive organ differentiation, occurs between weeks 6 and 12. The FDA prescribing information for CombiPatch advises that if pregnancy occurs during treatment, the drug should be discontinued immediately.

Do not assume a brief early exposure caused definite harm. But do get monitoring. Your clinician may recommend a detailed anatomy scan later in pregnancy, particularly to assess fetal genital development, given the androgenic profile of norethindrone acetate.

Human data on pregnancy exposure

The evidence gap here is real and large. There are no prospective registries tracking outcomes in women who were using CombiPatch or Climara Pro at conception. The safety signals we have come from:

1. Older oral progestin studies from the 1970s and 1980s, before current formulations existed
2. Levonorgestrel IUD data during accidental pregnancy (where systemic absorption is minimal)
3. Animal reproductive toxicity studies required for FDA approval

A 2018 Cochrane review of progestogen use in early pregnancy found no increased risk of congenital anomalies with progesterone specifically, but explicitly excluded synthetic 19-nortestosterone derivatives from its safety endorsement. This distinction matters. Micronized progesterone is not the same as norethindrone or levonorgestrel.

ACOG Committee Opinion acknowledges that data on progestin safety in pregnancy remain limited and that synthetic progestins with androgenic activity carry theoretical teratogenic risk, and clinicians should counsel women accordingly when exposure has occurred.

Lactation: estradiol, norethindrone, and levonorgestrel in breast milk

All three hormones in these patches transfer into breast milk to some degree.

LactMed, the NIH's authoritative drug-and-lactation database, notes that estrogens at pharmacologic doses reduce milk production by suppressing prolactin. This is a well-established mechanism: estrogen inhibits prolactin-mediated milk synthesis. Using a menopausal estradiol patch while breastfeeding could reduce your milk supply, potentially significantly.

Synthetic progestins also transfer into breast milk. While the absolute quantities are small, no safety threshold for infant exposure to norethindrone or levonorgestrel via breast milk has been established for newborns and infants. The World Health Organization's eligibility criteria for hormonal contraceptives during lactation advise avoiding combined estrogen-progestin methods in the first six months postpartum due to milk supply concerns. That guidance applies to contraceptive patches, but the underlying physiology is identical for a menopausal combination patch.

Do not use CombiPatch or Climara Pro while breastfeeding.

Who CombiPatch and Climara Pro are right for, and who they are not for

Right for

• Postmenopausal women with an intact uterus experiencing vasomotor symptoms (hot flashes, night sweats) who need endometrial protection without a separate progestogen pill
• Women in late perimenopause with confirmed cessation of ovulation and no possibility of pregnancy, who have discussed cardiovascular, breast, and VTE risk with their clinician
• Women within 10 years of menopause or under age 60 where the benefit-risk balance for hormone therapy is generally favorable, per The Menopause Society's 2022 hormone therapy position statement

Not right for

• Women who are pregnant
• Women who are trying to conceive, even if they are perimenopausal and unsure whether they are still ovulating
• Women who are breastfeeding
• Women with a history of estrogen-sensitive breast cancer, endometrial cancer, unexplained vaginal bleeding, active thromboembolism, or recent cardiovascular events, per FDA contraindication labeling
• Women under 45 who have not yet confirmed menopause with FSH testing and 12 months of amenorrhea

The perimenopausal TTC edge case

Some women are simultaneously dealing with perimenopause symptoms and have not yet given up on pregnancy. This is a real clinical scenario, and it deserves a direct answer. Perimenopause does not equal infertility. Women in perimenopause can and do ovulate irregularly, and unintended pregnancy in this group is more common than many assume. If you are perimenopausal and still having cycles, you need effective contraception unless you are actively trying to conceive with medical supervision. CombiPatch and Climara Pro are not contraceptives and will not protect you from pregnancy.

If you need symptom relief during perimenopause while you are still in the TTC window, speak with a reproductive endocrinologist who can design a plan that does not compromise your fertility or expose a potential pregnancy to inappropriate hormones.

What to use instead if you need hormone support while TTC

This is where specificity matters. The answer to "what should I use instead" depends on why you thought you needed the patch in the first place.

If you had vasomotor symptoms and were prescribed a combination patch

You likely have significant perimenopause-related estrogen fluctuation. For women still in the TTC window, non-hormonal options for vasomotor symptoms include fezolinetant (Veoza), the first non-hormonal neurokinin 3 receptor antagonist FDA-approved for hot flashes, though its safety in pregnancy has not been established. Cognitive behavioral therapy and lifestyle modifications have Level I evidence for modest vasomotor symptom reduction.

If you need progesterone support in fertility cycles

Vaginal micronized progesterone (e.g., Endometrin 100 mg twice daily, Crinone 8% gel, or oral Prometrium 200 mg nightly) is the standard of care for luteal-phase support in fertility treatments. ASRM supports its use in IVF cycles and in women with recurrent pregnancy loss with a luteal-phase defect. This is not the same compound as the synthetic progestins in CombiPatch or Climara Pro.

If you have PCOS and estrogen/progesterone imbalance

Women with PCOS often have elevated androgens, irregular cycles, and varying estrogen exposure. Adding a synthetic androgenic progestin like norethindrone acetate or levonorgestrel to this picture is not appropriate in the TTC window. Your reproductive endocrinologist may instead use letrozole or clomiphene for ovulation induction, paired with cycle monitoring. Letrozole is now the first-line ovulation induction agent in PCOS per ASRM, with higher live-birth rates than clomiphene in this population.

The evidence gap: what we do not know

Women have been systematically underrepresented in pharmaceutical trials for decades, and this creates real blind spots in women's health prescribing. No randomized trial has ever enrolled women who were using menopausal combination patches and attempting conception. The safety statements in FDA labeling are derived from:

• Animal reproductive toxicity studies conducted as part of drug approval requirements
• Extrapolation from oral progestin and combined oral contraceptive data in pregnant women
• Case reports and pharmacovigilance databases

This does not mean the risk is zero. It means we cannot quantify it precisely. What we can say with certainty is that neither CombiPatch nor Climara Pro was developed, tested, or approved for use in women who are pregnant or trying to become pregnant, and no clinical body, including ACOG, ASRM, or The Menopause Society, recommends them in this context.

A 2020 systematic review in AJOG examining progestin exposure in early pregnancy found that while the evidence on congenital anomalies from progestin exposure is reassuring for micronized progesterone, synthetic 19-nortestosterone derivatives remain a category where clinicians should counsel patients about theoretical androgenic risk to a female fetus.

When the data are thin, the appropriate move is caution, not reassurance without evidence.

Talking to your clinician: what to say at your next appointment

If you were prescribed CombiPatch or Climara Pro and are now considering trying to conceive, bring these specific points to your appointment:

• Tell your clinician you are planning to attempt conception so they can transition you off the patch well before your first TTC cycle
• Ask whether your underlying symptoms (vasomotor, mood, sleep) have non-hormonal or bioidentical alternatives appropriate for the TTC window
• If you have ovarian reserve concerns or irregular cycles, request a referral to a reproductive endocrinologist before stopping your current hormone therapy without a plan
• Ask specifically about FSH, AMH, and antral follicle count testing to clarify your actual ovarian reserve before making assumptions about your fertility based on menopausal symptoms alone

Perimenopause symptoms do not always mean you cannot conceive. But the patch you are on was never meant to get you pregnant. It was meant to manage the transition away from reproductive function.